Graves’ Ophthalmopathy - Pipeline Insight, 2019

"Graves Ophthalmopathy - Pipeline Insight, 2019" report by outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves Ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves Ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves Ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves Ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Graves Ophthalmopathy Understanding
Graves Ophthalmopathy also known as Graves eye disease or Graves Orbitopathy is a problem that usually develops in people with an overactive thyroid caused by Graves disease. It is an autoimmune condition where the bodys immune system produces an antibody to cells in the thyroid gland causing an overproduction of thyroid hormones. It appears that the same antibody that can cause thyroid dysfunction may also have an ""attraction"" to tissues surrounding the eyes causing the onset of Graves Ophthalmopathy. The disease is categorized as mild, moderate, and severe. Some common symptoms of Graves Ophthalmopathy includes, feeling of irritation or grittiness in the eyes, redness or inflammation of the conjunctiva (the white part of the eyeball), excessive tearing or dry eyes, swelling of the eyelids, sensitivity to light, forward displacement or bulging of the eyes (called proptosis), and double vision. In more advanced eye disease there may also be decreased eye movement and eyelids, incomplete closure of the eye with corneal ulceration, compression of the optic nerve and rarely, loss of vision.
Graves Ophthalmopathy Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Graves Ophthalmopathy targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Graves Ophthalmopathy pipeline report covers 6+ companies. Some of the key players include HanAll Biopharma (HL 161), Horizon Therapeutics (Teprotumumab) etc.
The report is built using data and information traced from the researchers proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Graves Ophthalmopathy Analytical Perspective by DelveInsight
In-depth Graves Ophthalmopathy Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
Graves Ophthalmopathy Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
The Graves Ophthalmopathy report provides an overview of therapeutic pipeline activity for Graves Ophthalmopathy across the complete product development cycle including all clinical and non-clinical stages
It comprises of detailed profiles of Graves Ophthalmopathy therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
Detailed Graves Ophthalmopathy Research and Development progress and trial details, results wherever available, are also included in the pipeline study
Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Graves Ophthalmopathy
Reasons to Buy
Establish a comprehensive understanding of the current pipeline scenario across Graves Ophthalmopathy to formulate effective R&D strategies
Assess challenges and opportunities that influence Graves Ophthalmopathy R&D
Develop strategic initiatives by understanding the focus areas of leading companies.
Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
Get in detail information of each product with updated information on each project along with key milestones
Devise Graves Ophthalmopathy in licensing and out licensing strategies by identifying prospective partners with progressing projects for Graves Ophthalmopathy to enhance and expand business potential and scope
Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

List Of Tables

Table 1. Graves Ophthalmopathy Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Graves Ophthalmopathy Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

List Of Figures

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Graves Ophthalmopathy companies collaborations, Licensing, Acquisition Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Graves Ophthalmopathy Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available